目的 探討枳實(shí)消痞丸聯(lián)合復(fù)方阿嗪米特治療功能性消化不良的臨床療效。方法 選取2016年5月—2017年5月在濟(jì)寧市第一人民醫(yī)院就診的功能性消化不良患者110例，依據(jù)用藥的差別分為對(duì)照組（55例）和治療組（55例）。對(duì)照組口服復(fù)方阿嗪米特腸溶片，150 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服枳實(shí)消痞丸，6 g/次，3次/d。兩組均連續(xù)治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀評(píng)分、健康問(wèn)卷（PHQ-15）、尼平消化不良指數(shù)（NDI）、焦慮自評(píng)量表（SAS）和抑郁自評(píng)量表（SDS）評(píng)分及血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為81.82%、96.36%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組餐后飽脹、食欲不振、反酸、上腹脹痛等癥狀評(píng)分均顯著降低（P<0.05）；且治療組各臨床癥狀評(píng)分顯著低于對(duì)照組（P<0.05）。治療后，兩組PHQ-15、NDI、SAS和SDS評(píng)分均明顯降低（P<0.05）；且治療組這些評(píng)分明顯低于對(duì)照組（P<0.05）。治療后，兩組血清神經(jīng)肽S受體-1（NPSR1）、降鈣素基因相關(guān)肽（CGRP）、胃動(dòng)素（MTL）、P物質(zhì)（SP）水平均明顯升高（P<0.05）；且治療組比對(duì)照組升高更明顯（P<0.05）。結(jié)論 枳實(shí)消痞丸聯(lián)合復(fù)方阿嗪米特治療功能性消化不良可有效改善患者臨床癥狀和生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Zhishi Xiaopi Pills combined with Compound Azintamide in treatment of functional dyspepsia. Methods Patients (110 cases) with functional dyspepsia in Jining No.1 People's Hospital from May 2016 to May 2017 were divided into control (55 cases) and treatment (55 cases) groups according to different treatments. Patients in the control group were po administered with Compound Azintamide Enteric-coated Tablets, 150 mg/time, three times daily. Patients in the treatment group were po administered with Zhishi Xiaopi Pills on the basis of the control group, 6 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, PHQ-15, NDI, SAS, and SDS scores, and serum markers in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.82% and 96.36%, respectively, and there were differences between two groups (P < 0.05). After treatment, the postprandial fullness, anorexia, acid reflux, distention and pain of the upper abdomen scores in two groups were significantly decreased (P < 0.05). And these clinical symptom scores in the treatment group were more obviously lower than those in the control group (P < 0.05). After treatment, the PHQ-15, NDI, SAS, and SDS scores in two groups were significantly decreased (P < 0.05). And these scores in the treatment group were more significantly lower than those in the control group (P < 0.05). After treatment, the serum NPSR1, CGRP, MTL and SP levels in two groups were significantly increased (P < 0.05). And the serum markers levels in the treatment group were more significantly higher than those in the control group (P < 0.05). Conclusion Zhishi Xiaopi Pills combined with Compound Azintamide can effectively improve the clinical symptoms and quality of life in treatment of functional dyspepsia, which has a certain clinical application value.